The FDA Said No to Moderna. Then the President Called.
The FDA refused to even review Moderna's mRNA flu vaccine application. Then, according to Politico, the President called the FDA commissioner to the White House. A week later, the agency reversed course. What that means for the future of drug regulation is worth paying attention to.
Imagine you apply for a job. The company rejects your application without even reading your résumé. Then, about a week later, they call you back and say they'd love to review it after all.
Now imagine the reason they changed their mind is because the President of the United States got angry.
That's essentially what happened to Moderna's mRNA flu vaccine earlier this year. And it's raising uncomfortable questions about who's really calling the shots at the FDA.
A Door Slams Shut
In early February 2026, the FDA did something unusual. It sent Moderna a "refuse-to-file" letter for its next-generation mRNA flu vaccine, mRNA-1010. That's not a rejection after review; it's a rejection before review. The agency wouldn't even look at the application.
The FDA's reasoning? Moderna's clinical trial used the wrong comparison. The study measured the new vaccine against a standard-dose flu shot, but for people 65 and older, the recommended standard of care is a high-dose vaccine. In the FDA's view, Moderna hadn't proven its product was the best available option. The data, the agency said, didn't meet the bar for "adequate and well-controlled."
For Moderna, this was a gut punch. The same application had already been accepted for review in the EU, Canada, and Australia. But the FDA wasn't budging.
Or so it seemed.
A Phone Call Changes Everything
According to Politico, citing two people familiar with the details, President Donald Trump summoned FDA Commissioner Marty Makary to the White House shortly after the refusal became public. Trump was frustrated, not just about the Moderna decision, but about the FDA's broader vaccine policies.
CNN's reporting was blunter: Trump "berated" Makary over the decision.
What happened next was striking. Roughly one week after rejecting Moderna's application, the FDA reversed course. The agency granted Moderna a high-priority "Type A" meeting (think of it as a regulatory 911 call), and the two sides hammered out a new path forward. Moderna would split its application into two age groups: , and , with a requirement to run a follow-up study after the product hit the market.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
full approval for adults 50 to 64
accelerated approval for adults 65 and older
The FDA accepted the amended filing and set August 5, 2026 as the target decision date, fast enough to potentially get the vaccine out for the 2026–27 flu season.
The Official Story vs. the Obvious Timeline
The White House denied everything. A senior official told Politico the reporting was "not accurate" and insisted the FDA's decision-making was independent. Another official said, "Nothing the FDA has done recently on this issue was pre-coordinated" with the White House.
HHS spokesperson Andrew Nixon indicated that the FDA had engaged in discussions with Moderna since the rejection and had opted to accept a revised plan.
That's technically true. But it sidesteps the elephant in the room. The FDA went from "we won't even read your application" to "sure, let's figure this out" in about seven days. And those seven days just happened to include a presidential meeting where, according to multiple news outlets, the commander-in-chief made his displeasure very clear.
Former FDA chief scientist Jesse Goodman captured the tension perfectly. He called the final regulatory path "very reasonable," but criticized the way the agency got there as an unfortunate and poorly handled process.
This Didn't Happen in a Vacuum
To understand why this episode matters, you need to zoom out. The FDA's vaccine division has been through a rough stretch.
In April 2025, Peter Marks, the agency's top vaccine regulator, was effectively forced out after clashing with HHS Secretary Robert F. Kennedy Jr. over vaccine data access. Marks had been the longtime director of the Center for Biologics Evaluation and Research (CBER) and was the architect of the COVID-era mRNA vaccine authorizations. In his resignation letter, he cited an "unprecedented assault on scientific truth."
Marks' replacement? Vinay Prasad, a physician known for his public critiques of certain COVID-19 policies. The new CBER director operates under an HHS Secretary who has spent years questioning vaccine safety.
The formal rules for approving vaccines haven't changed. But the people interpreting those rules have. Think of it like a basketball game where the rulebook stays the same, but an entirely new set of refs takes the court. The calls are going to feel different.
Wall Street Liked It. Scientists, Not So Much.
Analysts reacted to the reversal with cautious optimism. TD Cowen's Tyler Van Buren noted that the backlash appeared to push the FDA to "quickly find an acceptable solution." Citi's Geoff Meacham said the reversal could restore a revenue stream that had been "in limbo."
But Leerink's Mani Foroohar called it a "meaningful positive" with caveats: uncertainty remains around the review outcome, the post-marketing study design, and (most importantly for Moderna's bottom line) whether the FDA will eventually greenlight Moderna's combo flu-plus-COVID vaccine, mRNA-1083, which hit its own regulatory wall in 2025.
By mid-June, the FDA's vaccine advisory committee voted 9-0 that the benefits of Moderna's mRNA flu shot outweigh the risks for adults 50 and older. That's a unanimous endorsement, which suggests the science was always solid. The question was never really about the data.
Why This Should Make You Nervous
The FDA's job is straightforward in theory: evaluate whether a product is safe and effective based on evidence. Political pressure, from any direction, corrodes that mission. And this isn't the first time it's happened.
During the first Trump administration, the White House pushed the FDA on hydroxychloroquine and made a rare presidential appearance at a convalescent plasma authorization. Under Obama, HHS Secretary Kathleen Sebelius overrode the FDA's recommendation on Plan B contraceptive access. Political meddling in drug regulation is bipartisan and persistent.
But the current environment feels different in degree, if not in kind. The top vaccine regulator was pushed out for defending scientific independence. His replacement leads an agency operating under an HHS secretary who is openly skeptical of vaccines. And now there's a credible report that a presidential phone call may have reversed a major regulatory decision within days.
For biotech companies, the practical takeaway is unsettling: regulatory decisions may be more volatile and less predictable than in prior administrations, especially for anything touching vaccines or mRNA technology.
For the rest of us, the stakes are simpler. The FDA is the gatekeeper between experimental medicines and your medicine cabinet. When that gate swings open or shut based on who called whom, the system that's supposed to protect public health starts looking a lot less reliable.
Moderna's flu vaccine might turn out to be excellent. The science may fully support approval. But the process that got it back on track? That's the part worth worrying about.
Clinical & Regulatory5 min read
The FDA Just Gave Itself a Live Feed Into Clinical Trials
The FDA is getting a live data feed from two oncology trials run by AstraZeneca and Amgen, ditching the decades-old model of waiting months between data checkpoints. If it works, drug development timelines could shrink by years.
